Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
A legfontosabb adatok
- Ki végzi
- Chongqing Precision Biotech Co., Ltd
- Hol
- Hangzhou (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 10 fő, tervezett
- Kezdés
- 2024. júl. 2.
- Várható befejezés
- 2028. júl. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- CD19-targetd CAR-T
- A regiszteradat frissítve
- 2024. augusztus 26.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for children and teens with juvenile dermatomyositis (JDM) that has not responded to usual treatment. They will receive CD19-targeted CAR-T cell therapy.
- Életkor
- 5 years up to under 17 years.
- Nem
- All sexes can join.
- A betegség stádiuma
- Refractory JDM: the disease did not respond to, or was not tolerated with, standard treatment. Also at least one of these: fast-moving disease or disease in the lungs, heart or gut; calcium deposits under the skin, in muscles or joints; or rashes or skin ulcers that keep coming back. People with SRP or HMGCR antibody-positive immune-mediated necrotizing myopathy can also join. Heart, kidney, liver and lung function must be basically normal.
- Korábbi kezelés
- Must have had glucocorticoids (steroids) and at least 2 immunosuppressant drugs for at least 6 months, without enough benefit or with intolerance. Must not have had CAR T cell therapy before.
- Biomarker vagy leletérték
- A positive myositis-specific antibody test, such as MDA-5, NXP2, TIF-1γ or Ro-52. LVEF ≥55%, eGFR≥30ML/min/1.73m2, AST and ALT≤3.0 ULN, total bilirubin ≤2.0×ULN, SpO2≥92%.
A részvétel fő kizáró okai
- Previous CAR T cell therapy.
- Another autoimmune or rheumatic disease besides JDM, or a serious immune deficiency.
- Serious or active infection, such as tuberculosis, hepatitis B or C, HIV, syphilis or CMV.
- Cancer now or in the past, except removed skin basal cell carcinoma.
- Serious heart problems, an organ or stem cell transplant within 3 months, or a positive pregnancy test.
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Age: ≥5 years and <17 years old
- To meet the diagnostic criteria of JDM, four or five of the following criteria must be met:① symmetrical proximal muscle weakness; ②Characteristic skin changes, including positive dermatitis (purplish red rash on upper eyelid with periorbital edema) and Gottron papules (red patchy squamous papules on the back of knuckles); ③ The level of one muscle enzyme in serum was increased; ④ Positive myositis antibody; ⑤Electromyography shows denervation and myopathy; ⑥ Muscle biopsies showed necrosis and inflammation
- The classification criteria of RJDM must meet ① and any of the criteria②-④: ① Patients who are intolerant or unresponsive to glucocorticoids and at least 2 immunosuppressants, adequate hormone therapy and duration of at least 6 months; ② The disease progresses rapidly and/or involves organs such as lungs, heart and gastrointestinal tract; ③ Calcification of subcutaneous or muscle and joint tissues; ④ Repeated rashes or skin ulcers
- myositis specific antibody positive, defined as MDA-5, NXP2, TIF-1γ, Ro-52 and any other positive
- If the patient has SRP or HMGCR antibody positive immune-mediated necrotizing myopathy equivalent to RJDM, the inclusion criteria of (2) - (4) can be met
- The functions of important organs are basically normal:; ① Cardiac function: left ventricular ejection fraction (LVEF) ≥55%, no obvious abnormality in electrocardiogram; ② Renal function: eGFR≥30ML/min/1.73m2; ③ Liver function: AST and ALT≤3.0 ULN, total bilirubin ≤2.0×ULN; ④ Lung function: Lung function is basically normal, SpO2≥92%
- Have the criteria for simple or intravenous blood collection, and no other contraindications for cell collection
- The subject of childbearing age has a negative urine pregnancy test result and agrees to take effective contraceptive measures during the test period until 1 year after the infusion
- The patient or his/her guardian agrees to participate in this clinical trial and signs an informed consent indicating that he/she understands the purpose and procedure of this clinical trial and is willing to participate in the study
Ki nem vehet részt
- Had previously received CAR T cell therapy
- Congenital heart disease or history of acute myocardial infarction within 6 months before screening, or severe arrhythmias (including multi-source frequent supraventricular tachycardia, ventricular tachycardia, etc.); Or combined with a large number of pericardial effusion, serious myocarditis, etc.; Or patients with unstable vital signs who need hypertensive drugs to maintain their blood pressure
- There is an active or uncontrollable infection that requires systemic treatment within 1 week prior to screening
- Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months before screening; Acute graft-versus-host disease (GVHD) of grade 2 or above was present within 2 weeks prior to screening
- Had received live vaccine within 4 weeks prior to screening
- Patients who had participated in other clinical trials within 3 months prior to enrollment
- Have other autoimmune or rheumatic diseases other than JDM
- accompanied by serious infectious diseases, including but not limited to active tuberculosis, latent tuberculosis infection, active viral hepatitis, etc
- Evidence of active malignant disease or diagnosis of malignant tumor (including hematological malignancies and solid tumors, except resected and cured skin basal cell carcinoma)
- suffering from other diseases that require long-term use of glucocorticoids or immunosuppressants
- Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; Or hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; Or positive for human immunodeficiency virus (HIV) antibodies; Or syphilis test positive; Or cytomegalovirus (CMV) DNA test positive
- Patients with known malignant diseases such as tumors before screening
- primary immunodeficiency or severe secondary immunodeficiency that has not been corrected
- Positive blood pregnancy test
- Situations in which other investigators consider it inappropriate to participate in the study
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 5 és 17 év között vagy?
Helyszínek itt: Kína
- Children's Hospital, Zhejiang University School of MedicineHangzhou, KínaContact: Meiping Lu, M.DRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).
A vizsgálat csoportja
- CD19-targeted CAR-TA vizsgált kezelés
The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).
Kezelés: CD19-targetd CAR-T
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Clinical Study of CD19 Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06569472: ki vehet részt
- A regiszteradat frissítve
- 2024. augusztus 26.